275 related articles for article (PubMed ID: 27540314)
1. Experimental treatment of antipsychotic-induced movement disorders.
Shireen E
J Exp Pharmacol; 2016; 8():1-10. PubMed ID: 27540314
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
3. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
El-Sayeh HG; Rathbone J; Soares-Weiser K; Bergman H
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000458. PubMed ID: 29342497
[TBL] [Abstract][Full Text] [Related]
4. [Dysphagia or dysphagias during neuroleptic medication?].
Chaumartin N; Monville M; Lachaux B
Encephale; 2012 Sep; 38(4):351-5. PubMed ID: 22980477
[TBL] [Abstract][Full Text] [Related]
5. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
Barnes TR; McPhillips MA
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
[TBL] [Abstract][Full Text] [Related]
6. Vitamin E for antipsychotic-induced tardive dyskinesia.
Soares-Weiser K; Maayan N; Bergman H
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000209. PubMed ID: 29341067
[TBL] [Abstract][Full Text] [Related]
7. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
8. Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Bergman H; Soares-Weiser K
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000204. PubMed ID: 29341071
[TBL] [Abstract][Full Text] [Related]
9. Calcium channel blockers for antipsychotic-induced tardive dyskinesia.
Essali A; Soares-Weiser K; Bergman H; Adams CE
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD000206. PubMed ID: 29578611
[TBL] [Abstract][Full Text] [Related]
10. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of antipsychotic drug-induced movement disorders.
Casey DE
J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
Lockwood JT; Remington G
Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
[TBL] [Abstract][Full Text] [Related]
13. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Bordia T; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Mar; 340(3):612-9. PubMed ID: 22144565
[TBL] [Abstract][Full Text] [Related]
14. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
Haleem DJ
Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
[TBL] [Abstract][Full Text] [Related]
15. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
16. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
[TBL] [Abstract][Full Text] [Related]
17. Oxidative mechanisms and tardive dyskinesia.
Lohr JB; Kuczenski R; Niculescu AB
CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
[TBL] [Abstract][Full Text] [Related]
18. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
19. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.
Essali A; Deirawan H; Soares-Weiser K; Adams CE
Cochrane Database Syst Rev; 2011 Nov; (11):CD000206. PubMed ID: 22071797
[TBL] [Abstract][Full Text] [Related]
20. [Neuroleptic-induced movement disorders: historical perspectives].
Wolf MA; Yassa R; Llorca PM
Encephale; 1993; 19(6):657-61. PubMed ID: 12404786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
